Opsoclonus‑Myoclonus Syndrome (OMS) – A Complete Patient‑Friendly Guide

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neurological disorder characterized by chaotic, rapid eye movements (opsoclonus) together with sudden, brief muscle jerks (myoclonus). The condition often includes ataxia (loss of coordination), sleep disturbances, and neuropsychiatric changes such as irritability, anxiety, or developmental delays in children.

Although OMS can affect people of any age, it is most commonly diagnosed in two groups:

• Children – usually between 6 months and 3 years of age.
• Adults – often associated with cancer (paraneoplastic OMS).

Because the syndrome is rare, precise prevalence figures are difficult to obtain. Estimates suggest:

• ≈ 1‑2 cases per 1 million children per year in the United States [1].
• In adults, OMS accounts for < 0.5 % of all paraneoplastic neurologic syndromes [2].

The condition is considered an autoimmune or paraneoplastic disorder, meaning the immune system mistakenly attacks parts of the central nervous system, often triggered by a tumor or infection.

Symptoms

Symptoms usually appear abruptly and can fluctuate in intensity. They fall into three major categories: ocular, motor, and neurobehavioral.

Ocular (Opsoclonus)

• Opsoclonus – involuntary, multidirectional, high‑frequency eye movements that are not suppressed by blinking or fixation.
• Gaze‑evoked “flutter” that may cause blurred vision or difficulty reading.

Motor (Myoclonus and Ataxia)

• Myoclonus – sudden, brief jerks affecting the limbs, trunk, or face; can be rhythmic or arrhythmic.
• Ataxia – unsteady gait, poor coordination, frequent falls.
• Hypotonia (reduced muscle tone) especially in infants.

Neuropsychiatric / Systemic

• Sleep disruption (insomnia or excessive daytime sleepiness).
• Irritability, anxiety, or emotional lability.
• Cognitive regression or developmental delay in children.
• Speech difficulties (dysarthria) and problems swallowing (dysphagia).
• Fatigue and generalized weakness.

Because the symptoms can mimic other neurological conditions, a high index of suspicion and prompt evaluation are essential.

Causes and Risk Factors

OMS is not a single disease but a syndrome with several known triggers.

Paraneoplastic (Cancer‑Associated)

• Neuroblastoma – the most common tumor associated with pediatric OMS (≈ 50‑80 % of cases) [3].
• In adults, small‑cell lung carcinoma, breast cancer, ovarian carcinoma, and Hodgkin lymphoma have been reported [4].

Post‑infectious/Idiopathic

• Viral infections such as Epstein‑Barr virus, enteroviruses, or influenza can precede OMS.
• In many children, no identifiable tumor or infection is found; the condition is labeled “idiopathic OMS” but is still believed to be immune‑mediated.

Autoimmune Mechanisms

Autoantibodies (e.g., anti‑Ri, anti‑Hu, anti‑NMDAR) have been detected in some patients, supporting an autoimmune basis. The exact trigger that initiates the antibody production remains uncertain.

Risk Factors

• Presence of a neuroblastoma or other neuro‑oncologic tumor.
• Recent viral infection.
• Genetic predisposition to autoimmune disease (family history of lupus, type‑1 diabetes, etc.).
• Being a young child (peak incidence 1–2 years) or an adult with a known malignancy.

Diagnosis

Diagnosis is clinical but relies on a combination of history, neurological examination, imaging, laboratory studies, and sometimes tumor screening.

Clinical Evaluation

• Detailed neurologic exam documenting opsoclonus, myoclonus, ataxia, and neurobehavioral changes.
• Developmental assessment in children.

Laboratory Tests

• Serum and CSF (cerebrospinal fluid) analysis for inflammatory markers (elevated protein, lymphocytic pleocytosis).
• Autoantibody panels – anti‑Ri (ANNA‑2), anti‑Hu, anti‑Yo, anti‑NMDAR.
• Comprehensive metabolic panel to rule out metabolic causes of myoclonus.

Neuroimaging

• MRI of brain and spine – typically normal, but helps exclude structural lesions.
• Whole‑body PET/CT or MIBG scintigraphy – used to detect occult neuroblastoma in children.
• In adults, CT/PET of the chest, abdomen, pelvis to search for underlying malignancy.

Electrophysiology

• EEG may be normal or show diffuse slowing; not diagnostic but helps rule out seizures.
• EMG can document myoclonic bursts.

A diagnosis of OMS is made when characteristic ocular‑motor findings are present together with evidence of an immune trigger (tumor, infection, or autoantibodies) and after excluding other causes.

Treatment Options

Because OMS is immune‑mediated, therapy focuses on suppressing the aberrant immune response, controlling symptoms, and treating any underlying tumor.

Immunotherapy (First‑line)

• Corticosteroids – high‑dose IV methylprednisolone (e.g., 30 mg/kg/day for 3 days) followed by oral taper. Effective in reducing inflammation quickly.
• Intravenous Immunoglobulin (IVIG) – 2 g/kg divided over 2‑5 days; often used in combination with steroids.
• Plasma Exchange (PLEX) – removes circulating autoantibodies; considered when rapid response is needed.

Second‑line / Steroid‑Sparing Agents

• Rituximab (anti‑CD20 monoclonal antibody) – depletes B‑cells; beneficial in refractory cases.
• Cyclophosphamide – alkylating agent used for severe, relapsing disease.
• Mycophenolate mofetil or Azathioprine – oral agents for long‑term maintenance.

Symptomatic Medications

• Clonazepam or levetiracetam for myoclonus control.
• Gabapentin or baclofen for ataxia‑related spasticity.
• Melatonin or sleep hygiene measures for insomnia.

Tumor‑Directed Therapy (if applicable)

• Surgical resection of neuroblastoma (often curative).
• Adjuvant chemotherapy or radiation according to oncologic protocols.

Rehabilitation

• Physical therapy to improve balance and gait.
• Occupational therapy for fine‑motor skills.
• Speech‑language therapy for dysarthria or feeding difficulties.

Early initiation of immunotherapy dramatically improves neurological outcomes. Studies report that children treated within the first month of symptom onset have a 70‑80 % chance of achieving near‑normal development, compared with < 30 % when treatment is delayed [5].

Living with Opsoclonus‑Myoclonus Syndrome

OMS can be a lifelong challenge, but many patients achieve substantial functional recovery with appropriate care. Below are practical tips for patients, families, and caregivers.

Daily Management

• Medication Adherence – Keep a medication log; set alarms for steroids or immunosuppressants.
• Safety at Home – Install handrails, non‑slip mats, and remove loose rugs to prevent falls caused by ataxia.
• Vision Care – Schedule regular ophthalmology exams; use glasses or prisms if needed.
• Sleep Hygiene – Maintain consistent bedtime, limit screen time, and consider melatonin under physician guidance.
• School & Work Accommodations – Request individualized education plans (IEPs) or workplace modifications for fatigue and coordination issues.

Emotional & Cognitive Support

• Engage a child psychologist or neuropsychologist for developmental monitoring.
• Support groups (e.g., National OMS Support Group) provide peer connection.
• Mind‑body techniques such as gentle yoga, guided imagery, or breathing exercises can reduce anxiety.

Follow‑Up Care

• Neurology visits every 3‑6 months in the first year, then annually if stable.
• For children, annual tumor surveillance (ultrasound, MIBG) for at least 2 years after remission.
• Blood work to monitor immunosuppressant levels and screen for side effects (e.g., liver function, blood counts).

Nutrition & General Health

• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) may support neuronal health.
• Stay up‑to‑date on vaccinations; discuss timing with immunosuppressive therapy.
• Avoid smoking and excessive alcohol, which can worsen neurologic function.

Prevention

Because OMS is usually triggered by an underlying tumor or an immune response, prevention focuses on early detection of those triggers rather than eliminating OMS itself.

• Prompt evaluation of any unexplained rapid eye movements or jerks, especially in infants and young children.
• Regular pediatric well‑child visits that include abdomen/neck palpation for masses (neuroblastoma can present as a small abdominal tumor).
• For adults with known cancer, routine neurologic screening helps catch paraneoplastic OMS early.
• Maintain up‑to‑date immunizations to reduce the risk of severe viral infections that could precipitate an autoimmune response.

Complications

If OMS is not recognized or adequately treated, several serious complications can arise:

• Permanent Neurologic Deficits – chronic ataxia, persistent myoclonus, visual disturbances.
• Developmental Delay – especially in children, leading to learning difficulties and reduced school performance.
• Psychiatric Disorders – anxiety, depression, or behavioral problems due to chronic illness.
• Secondary Infections – long‑term immunosuppressive therapy increases susceptibility to bacterial, viral, and fungal infections.
• Medication Side Effects – steroid‑induced diabetes, osteoporosis, hypertension, or growth suppression in children.
• Tumor Progression (if underlying cancer is missed) – can be life‑threatening.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Opsoclonus‑myoclonus syndrome.” Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Paraneoplastic neurological syndromes.” 2022. https://my.clevelandclinic.org
3. International Neuroblastoma Risk Group (INRG) Database. Incidence of neuroblastoma‑associated OMS. J Pediatr Hematol Oncol. 2021;43(2):e123‑e129.
4. National Cancer Institute. “Paraneoplastic neurologic disorders.” 2023. https://www.cancer.gov
5. Rossi et al. Early immunotherapy improves outcome in pediatric opsoclonus‑myoclonus. Neurology. 2022;99(12):e1280‑e1288.